Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Intracerebral hemorrhage is the least treatable form of stroke. We performed this phase 3 trial to confirm a previous study in which recombinant activated factor VII (rFVIIa) reduced growth of the hematoma and improved survival and functional outcomes. METHODS: We randomly assigned 841 patients with intracerebral hemorrhage to receive placebo (268 patients), 20 microg of rFVIIa per kilogram of body weight (276 patients), or 80 microg of rFVIIa per kilogram (297 patients) within 4 hours after the onset of stroke. The primary end point was poor outcome, defined as severe disability or death according to the modified Rankin scale 90 days after the stroke. RESULTS: Treatment with 80 microg of rFVIIa per kilogram resulted in a significant reduction in growth in volume of the hemorrhage. The mean estimated increase in volume of the intracerebral hemorrhage at 24 hours was 26% in the placebo group, as compared with 18% in the group receiving 20 microg of rFVIIa per kilogram (P=0.09) and 11% in the group receiving 80 microg (P<0.001). The growth in volume of intracerebral hemorrhage was reduced by 2.6 ml (95% confidence interval [CI], -0.3 to 5.5; P=0.08) in the group receiving 20 microg of rFVIIa per kilogram and by 3.8 ml (95% CI, 0.9 to 6.7; P=0.009) in the group receiving 80 microg, as compared with the placebo group. Despite this reduction in bleeding, there was no significant difference among the three groups in the proportion of patients with poor clinical outcome (24% in the placebo group, 26% in the group receiving 20 microg of rFVIIa per kilogram, and 29% in the group receiving 80 microg). The overall frequency of thromboembolic serious adverse events was similar in the three groups; however, arterial events were more frequent in the group receiving 80 microg of rFVIIa than in the placebo group (9% vs. 4%, P=0.04). CONCLUSIONS: Hemostatic therapy with rFVIIa reduced growth of the hematoma but did not improve survival or functional outcome after intracerebral hemorrhage. (ClinicalTrials.gov number, NCT00127283 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
(1965) · PubMed · Cited by 14,925
ASSESSMENT OF COMA AND IMPAIRED CONSCIOUSNESS
Teasdale, G., & Jennett, B. (1974) · The Lancet · doi:10.1016/s0140-6736(74)91639-0 · Cited by 13,215
Functional evaluation : Barthel index
Mahonery, F. I. (1965) · Medical Entomology and Zoology · Cited by 12,762
Interobserver agreement for the assessment of handicap in stroke patients
van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988) · Stroke · doi:10.1161/01.str.19.5.604 · Cited by 6,512
Measurements of acute cerebral infarction: a clinical examination scale.
Brott, T., Adams, H. P., Olinger, C. P., Marler, J. R., Barsan, W. G., Biller, J., Spilker, J., Holleran, R., Eberle, R., & Hertzberg, V (1989) · Stroke · doi:10.1161/01.str.20.7.864 · Cited by 5,911
WILSON, J. T. L., PETTIGREW, L. E. L., & TEASDALE, G. M. (1998) · Journal of Neurotrauma · doi:10.1089/neu.1998.15.573 · Cited by 2,386
The ICH Score: A Simple, Reliable Grading Scale for Intracerebral Hemorrhage
Hemphill, J. C., Bonovich, D. C., Besmertis, L., Manley, G. T., & Johnston, S. C. (2001) · Stroke · doi:10.1161/01.str.32.4.891 · Cited by 2,196
Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality.
Broderick, J. P., Brott, T. G., Duldner, J. E., Tomsick, T., & Huster, G. (1993) · Stroke · doi:10.1161/01.str.24.7.987 · Cited by 1,746
Self-citationEarly Hemorrhage Growth in Patients With Intracerebral Hemorrhage
Brott, T., Broderick, J., Kothari, R., Barsan, W., Tomsick, T., Sauerbeck, L., Spilker, J., Duldner, J., & Khoury, J. (1997) · Stroke · doi:10.1161/01.str.28.1.1 · Cited by 1,477
Self-citationHematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage
Davis, S. M., Broderick, J., Hennerici, M., Brun, N. C., Diringer, M. N., Mayer, S. A., Begtrup, K., & Steiner, T. (2006) · Neurology · doi:10.1212/01.wnl.0000208408.98482.99 · Cited by 1,168
Self-citation
Research works printed but not linked: 2
- Zimmerman RD, 2006, AJNR Am J Neuroradiol, 27, 666
- Mahoney FI, 1965, Md State Med J, 14, 61
Cited by
Items 601–700 of 1,000
Stroke: management and prevention
Gbinigie, I. I., Reckless, I. P., & Buchan, A. M. (2016) · Medicine · doi:10.1016/j.mpmed.2016.06.003 · Cited by 16
Watson, V. L., Louis, N., Seminara, B. V., Muizelaar, J. P., & Alberico, A. M. (2017) · Neurosurgery · doi:10.1093/neuros/nyx072 · Cited by 15
Haas, K., Purrucker, J. C., Rizos, T., Heuschmann, P. U., & Veltkamp, R. C. (2018) · European Stroke Journal · doi:10.1177/2396987318812644 · Cited by 14
An update on neurocritical care for intracerebral hemorrhage
Reyes, R. G., Viswanathan, M., & Aiyagari, V. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1618709 · Cited by 16
Hu, X., Fang, Y., Li, H., Liu, W., Lin, S., Fu, M., Li, X., Cao, X., Zhang, H., You, C., et al. (2013) · International Journal of Stroke · doi:10.1111/ijs.12187 · Cited by 15
Júnior, M. R., da Rocha, A. J., Saade, N., Maia, A. C. M., & Gagliardi, R. J. (2013) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20130124 · Cited by 14
Herrick, D. B., Ziai, W., Thompson, C. B., Lane, K., McBee, N. A., & Hanley, D. F. (2011) · Stroke · doi:10.1161/strokeaha.111.625749 · Cited by 14
Ultra-Early Hemostatic Therapy for Intracerebral Hemorrhage: Future Directions
Wartenberg, K. E., & Mayer, S. A. (2015) · Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences · doi:10.1159/000437117 · Cited by 14
Self-citationSpotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran
Siè, P. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s94167 · Cited by 16
“For example, in a large randomized, placebocontrolled trial, treatment of spontaneous acute intracerebral hemorrhage with recombinant activated factor VIIa (eptacog alfa or NovoSeven, Novonordisk, Bagsvaerd, Denmark) reduced growth of the hematoma but did not improve survival or functional outcome.(48) Added to the in…”
Management of neurologic complications of coagulopathies
VanDerWerf, J. D., & Kumar, M. A. (2017) · Handbook of clinical neurology · doi:10.1016/b978-0-444-63599-0.00040-5 · Cited by 16
Imaging-based outcome prediction in patients with intracerebral hemorrhage
Sporns, P. B., Kemmling, A., Minnerup, J., Hanning, U. M. P., & Heindel, W. L. (2018) · Acta Neurochirurgica · doi:10.1007/s00701-018-3605-x · Cited by 14
Collaborative Management Strategies for Drug Shortages in Neurocritical Care
Clark, S. L., Levasseur‐Franklin, K. E., Pajoumand, M., Barra, M. E., Armahizer, M. J., Patel, D. V., Chester, K. W., & Tully, A. P. (2019) · Neurocritical Care · doi:10.1007/s12028-019-00730-7 · Cited by 14
Liu, R., Huynh, T. J., Huang, Y., Ramsay, D. A., Hynynen, K., & Aviv, R. I. (2014) · Neurocritical Care · doi:10.1007/s12028-014-0071-z · Cited by 14
“Future plans are to study the effect of existing and novel hemostatic therapies [22] on varying rates of contrast leakage.”
BackgroundVenketasubramanian, N., Lee, C. F., Wong, K. S., & Chen, C. (2015) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12170 · Cited by 16
Caceres, J., Greer, D. M., Goldstein, J. N., Viswanathan, A., Suárez, J. I., Brau, L., Zacko, J. C., Lowenkopf, T., Miller, C., Shah, Q. A., et al. (2013) · Journal of vascular and interventional neurology · Cited by 14
Management of Intraoperative Coagulopathy
Bar‐Natan, M., & Hymes, K. B. (2018) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2018.06.007 · Cited by 15
The Neurocritical Care Research Network: NCRN
Suárez, J. I., Geocadin, R., Hall, C., Roux, P. D. L., Smirnakis, S. M., Wijman, C. A. C., & Zaidat, O. O. (2011) · Neurocritical Care · doi:10.1007/s12028-011-9612-x · Cited by 14
“istration of the calcium-channel blocker nimodipine increased the likelihood of good outcomes after subarachnoid hemorrhage [22, 23]; a policy of urgent surgical evacuation of hematomas or the administration of activated factor VII within 4 h of symptom onset did not result in improved clinical results after intracere…”
Critical Care of Patients With Acute Ischemic and Hemorrhagic Stroke
Lukovits, T. G., & Goddeau, R. (2011) · CHEST Journal · doi:10.1378/chest.10-1530 · Cited by 13
Shakya, M. R., Fu, F., Zhang, M., Shan, Y., Yu, F., Sun, S., & Lu, J. (2021) · BioMed Research International · doi:10.1155/2021/3919710 · Cited by 17
“HE was defined as an absolute growth of hematoma by at least 6ml (follow-up volume–initial volume), or a relative growth by at least 33% (absolute growth/initial volume) [4, 17].”
BackgroundStroke: management and prevention
Montagu, A., Reckless, I. P., & Buchan, A. M. (2012) · Medicine · doi:10.1016/j.mpmed.2012.06.007 · Cited by 15
Tratamiento de los accidentes cerebrovasculares en la fase aguda
Jacquens, A., Guidoux, C., Mathon, B., Clarençon, F., & Degos, V. (2020) · EMC - Anestesia-Reanimación · doi:10.1016/s1280-4703(20)43647-3 · Cited by 13
Sex Differences in Perihematomal Edema Volume and Outcome After Intracerebral Hemorrhage
Witsch, J., Cao, Q., Song, J. W., Luo, Y., Sloane, K. L., Rothstein, A., Favilla, C. G., Cucchiara, B. L., Kasner, S. E., Messe, S. R., et al. (2024) · Neurocritical Care · doi:10.1007/s12028-024-01945-z · Cited by 14
“…double-blind, placebo-controlled trial of recombinant activated factor VIIa (rFVIIa) for the treatment of spontaneous ICH that randomized 841 patients to receive one of the three treatments within 4 h of stroke onset: placebo, 20 μg of rFVIIa/kg body weight, or 80 μg of rFVIIa/kg body weight [17].”
InfluentialSelf-citationGuidelines for Use of Anticoagulation in Pregnancy
Fuller, K., Turner, G. W., Polavarapu, S., & Prabulos, A.-M. (2013) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2013.03.018 · Cited by 14
Moussouttas, M. (2011) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285611422267 · Cited by 13
“The similar phase III FAST study tested rF-VIIa (20 and 80 mg) versus placebo, enrolled over 800 patients, and administered treatment within a mean time of 160 min [Mayer et al. 2008].”
BackgroundMethodRehmani, R., Han, A., Hassan, J., & Farkas, J. (2016) · Emergency Radiology · doi:10.1007/s10140-016-1464-4 · Cited by 13
A contemporary review of therapeutic and regenerative management of intracerebral hemorrhage
Sadaf, H., Desai, V. R., Misra, V., Golanov, E. V., Hegde, M. L., Villapol, S., Karmonik, C., Regnier‐Golanov, A., Sayenko, D. G., Horner, P. J., et al. (2021) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51443 · Cited by 14
“A phase 3 RCT tested the efficacy and safety of rFVIIa (20 and 80 μg) for restricting hematoma growth among non-OAC ICH patients.(39) Though both doses demonstrated a significant reduction in hematoma growth, there were no differences in the proportion of patients with poor clinical outcomes between the treatment and…”
MethodRecombinant activated factor VII use in the emergency department
Fishman, P. E., Drumheller, B. C., Dubon, M. E., & Slesinger, T. L. (2008) · Emergency Medicine Journal · doi:10.1136/emj.2007.057158 · Cited by 13
Hematoma Expansion in ICH: Targeting Epidemiology or Biology?
Hemphill, J. C. (2019) · Neurocritical Care · doi:10.1007/s12028-019-00752-1 · Cited by 13
Al-Senani, F., Zhao, X., Grotta, J. C., Shirzadi, A., Strong, R., & Aronowski, J. A. (2011) · Translational Stroke Research · doi:10.1007/s12975-011-0108-y · Cited by 12
“No medical or surgical therapy to date has been shown to reduce morbidity or mortality after hemispheric ICH [3–10].”
Fu, F., Sun, S., Liu, L., Li, J., Su, Y., & Li, Y. (2018) · European Radiology · doi:10.1007/s00330-018-5415-1 · Cited by 12
“improve outcomes [8], perhaps because the patients without HE also received haemostatic therapy; these patients could not benefit from the haemostatic therapy and were also at risk for”
BackgroundMagnesium: pathophysiological mechanisms and potential therapeutic roles in intracerebral hemorrhage
Chang, J. J., Armonda, R., Goyal, N., & Arthur, A. S. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.251189 · Cited by 12
“…trials have targeted this first stage—the attenuation of hematoma volume expansion through blood pressure control (Anderson et al., 2013; Qureshi et al., 2016), surgical evacuation (Men-delow et al., 2013), and hemostasis (Mayer et al., 2008)—but have failed to demonstrate clinical efficacy.”
BackgroundWu, T., Liu, Y., Chen, J., Ho, C., Zhang, Y., & Su, M. (2022) · Neurological Sciences · doi:10.1007/s10072-022-06528-4 · Cited by 12
Rosso, M., Stengl, H., Scheitz, J. F., Lewey, J., Mayer, S. A., Yaghi, S. R., Kasner, S. E., & Witsch, J. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.035053 · Cited by 12
Self-citationNo evidence or no alternative? Taking responsibility for off‐label prescribing
Ghinea, N., Lipworth, W. L., Kerridge, I., & Day, R. O. (2012) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2012.02713.x · Cited by 12
The epidemic of pre-injury oral antiplatelet and anticoagulant use
Berndtson, A. E., & Coimbra, R. S. M. (2014) · European Journal of Trauma and Emergency Surgery · doi:10.1007/s00068-014-0404-9 · Cited by 12
“Several studies have demonstrated decreased expansion of intracerebral hemorrhage [72] and”
BackgroundCharacteristics of Randomized Trials Focusing on Stroke due to Intracerebral Hemorrhage
Tamborska, A., Poon, M. T. C., & Salman, R. A. (2018) · Stroke · doi:10.1161/strokeaha.117.019227 · Cited by 12
de Freitas, G. R., & Nagayama, M. (2009) · Cerebrovascular Diseases · doi:10.1159/000202007 · Cited by 12
Surgical management in treatment of Jehovah′s witness in trauma surgery in Indian subcontinent
Nishant, N., & Kumari, R. (2014) · Journal of Emergencies Trauma and Shock · doi:10.4103/0974-2700.136868 · Cited by 12
Blood Transfusion in the 21st Century
Friedman, M. T., Avadhani, V., Gilmore, S., & Madrigal, E. (2014) · Discoveries · doi:10.15190/d.2014.3 · Cited by 12
Moon, B. H., Jang, D., Han, Y.-M., Jang, K.-S., Huh, R., & Park, Y. S. (2014) · Journal of Korean Neurosurgical Society · doi:10.3340/jkns.2014.56.4.295 · Cited by 12
Cerebral hemorrhage treated with NovoSeven in acute promyelocytic leukemia
Nosari, A., Caimi, T. M., Zilioli, V. R., Molteni, A., Mancini, V., & Morra, E. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.605189 · Cited by 12
Intracerebral Hemorrhage in Patients Receiving Oral Anticoagulation Therapy
da Silva, I. R. F., & Provencio, J. J. (2013) · Journal of Intensive Care Medicine · doi:10.1177/0885066613488732 · Cited by 13
“It is worth mentioning that doses as high as 80 mcg/kg are associated with an increased incidence of thrombotic events, as shown by the FAST trial.(43) As with PCC, we argue rFVIIa should be readily available in an emergency, as it does not need compatibility testing or thawing.”
BackgroundMethodInfluentialRecognizing and Preventing Intracerebral Hematoma Expansion
Caplan, L. R. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.1899 · Cited by 12
Harrigan, M. R., & Deveikis, J. P. (2018) · Contemporary medical imaging · doi:10.1007/978-3-319-66779-9_17 · Cited by 12
Magnesium Sulfate and Hematoma Expansion: An Ancillary Analysis of the FAST-MAG Randomized Trial
Naidech, A. M., Shkirkova, K., Villablanca, J. P., Sanossian, N., Liebeskind, D. S., Sharma, L., Eckstein, M., Stratton, S., CONWIT, R. A., Hamilton, S., et al. (2022) · Stroke · doi:10.1161/strokeaha.121.037999 · Cited by 11
Hsu, C.-H., Chou, S., Kuo, L., Huang, S.-J., Yang, S., Lai, D., & Huang, A. P. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.817386 · Cited by 11
Clinical Trial Design in the Neurocritical Care Unit
Hall, C. E., Mirski, M. A., Palesch, Y. Y., Diringer, M. N., Qureshi, A. I., Robertson, C. S., Geocadin, R., Wijman, C. A. C., Roux, P. D. L., & Suárez, J. I. (2011) · Neurocritical Care · doi:10.1007/s12028-011-9608-6 · Cited by 11
“rFVIIa trial [44] I Acute ICH within 3 h of symptom onset 38 1,636 199 (12)”
BackgroundSelf-citationSolomon, D., Kim, B., Scultetus, A. H., Arnaud, F. G., Auker, C., Freilich, D., & McCarron, R. M. (2011) · Cytokine · doi:10.1016/j.cyto.2010.12.013 · Cited by 11
Qureshi, A. I., Tariq, N. A., Vazquez, G., Novitzke, J. M., Suri, M. F. K., Lakshminarayan, K., & Haines, S. J. (2010) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2010.05.014 · Cited by 11
Acute intracerebral haemorrhage: Grounds for optimism in management
Delcourt, C., & Anderson, C. S. (2012) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2012.05.018 · Cited by 11
“within 4 hours of ICH onset significantly reduced ICH expansion to a similar 50% relative degree to that seen in the initial phase 2b trial,(10) but with a discordant effect in this failing to translate into any improvement in survival or functional outcome at 90 days.(11,12)”
ResultAcute Treatment of Hypertensive Intracerebral Hemorrhage
Mirsen, T. R. (2010) · Current Treatment Options in Neurology · doi:10.1007/s11940-010-0096-3 · Cited by 11
“& Based on these studies, the routine use of rFVIIa in ICH is unwarranted [ 46 ], Class I].”
BackgroundBrophy, G. M., Candeloro, C. L., Robles, J. R., & Brophy, D. F. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r729 · Cited by 11
Efficacy of Laropiprant in Minimizing Brain Injury Following Experimental Intracerebral Hemorrhage
Ahmad, A. S., Mendes, M. S., Hernandez, D., & Doré, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-09994-5 · Cited by 11
Sharrock, M. F., Mould, W. A., Hildreth, M., Ryu, E. P., Walborn, N., Awad, I. A., Hanley, D. F., & Muschelli, J. (2022) · Journal of Neuroimaging · doi:10.1111/jon.12997 · Cited by 13
Yogendrakumar, V., Mayer, S. A., Steiner, T., Broderick, J. P., & Dowlatshahi, D. D. (2023) · Stroke · doi:10.1161/strokeaha.123.043209 · Cited by 11
Self-citationAdverse drug events associated with disorders of coagulation
Barletta, J. F., Cooper, B. E., & Ohlinger, M. J. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181de11f9 · Cited by 13
“Diprose et al (212) P, DB, RCT pilot study 20 (10 in each arm) Cardiac surgery requiring CPB Thromboembolic events Placebo: 1 stroke, 1 MI,1 death, rFVIIa: 1 stroke, 1 MI Boffard et al (88) P, DB, MC, RCT 143 Blunt trauma Serious ADEs Placebo 66%, rFVIIa 64% Thromboembolic ADEs Placebo 4%, rFVIIa 3% Death or critical…”
BackgroundInfluentialOutcomes studies in cerebrovascular neurosurgery
Sanchez, C. E., Ogilvy, C. S., & Carter, B. S. (2007) · Neurosurgical FOCUS · doi:10.3171/foc.2007.22.3.13 · Cited by 11
Zhang, D., Chen, J., Guo, J., Jiang, Y., Dong, Y., Chen, B. P.-C., Wang, J., & Hou, L. (2018) · World Neurosurgery · doi:10.1016/j.wneu.2018.03.048 · Cited by 11
Wilkes, S. L., McCormack, E. J., Kenney, K., Stephens, B., Passo, R. M., Harburg, L., Silverman, E., Moore, C. B., Bogoslovsky, T., Pham, D. L., et al. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00527 · Cited by 12
Lv, X., & Li, Q. (2020) · Brain Hemorrhages · doi:10.1016/j.hest.2020.05.001 · Cited by 11
Torbey, M. (2009) · Stroke · doi:10.1161/strokeaha.108.535757 · Cited by 11
Mengel, A., Siokas, V., Buesink, R., Roesch, S., Laichinger, K., Ferizi, R., Dardiotis, E., Sartor‐Pfeiffer, J., Single, C., Hauser, T., et al. (2024) · Neurocritical Care · doi:10.1007/s12028-024-02146-4 · Cited by 10
Evidence-Based Neurocritical Care
Goodman, D., & Kumar, M. A. (2013) · The Neurohospitalist · doi:10.1177/1941874413507928 · Cited by 10
“Recombinant factor VIIa (rFVIIa), a promoter of hemostasis, studied in the phase III multicenter Femoral Artery Stenting Trial (FAST) failed to show any improvement in mortality or functional outcome and only achieved a modest decrease in hematoma expansion despite the success of the previous safety trial.(6,7) Moreov…”
BackgroundApplicability of Clinical Trials in an Unselected Cohort of Patients With Intracerebral Hemorrhage
Hansen, B. M., Ullman, N. L., Norrving, B. G., Hanley, D. F., & Lindgren, A. G. (2016) · Stroke · doi:10.1161/strokeaha.116.014203 · Cited by 10
“ICH-volume, mL, median (IQR) 15 (5-43) 15 (5-31) 14 (4-62) 0.”
Correlation between Spot Sign and Intracranial Hemorrhage Expansion on Dual-Phase CT Angiography
Kim, H., Goo, J. H., Kwak, H. S., Hwang, S. B., & Chung, G. H. (2019) · Diagnostics · doi:10.3390/diagnostics9040215 · Cited by 10
“An increase of hematoma size >33% or >6 mL was considered significant enlargement [13,14].”
BackgroundTahara, S., Hattori, Y., Aso, S., Uda, K., Kumazawa, R., Matsui, H., Fushimi, K., Yasunaga, H., & Morita, A. (2023) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2023.107327 · Cited by 10
Rationale and Design of the Statin Use in Intracerebral Hemorrhage Patients (SATURN) Trial
Marchina, S., Yeatts, S. D., Foster, L. D., Janis, S., Shoamanesh, A., Khatri, P., Bernstein, K., Perlmutter, A., Stever, C., Heistand, E. C., et al. (2024) · Cerebrovascular Diseases · doi:10.1159/000538195 · Cited by 14
Self-citationSex Modifies the Severity and Outcome of Spontaneous Intracerebral Hemorrhage
Rivier, C. A., Renedo, D. B., Marini, S., Magid-Bernstein, J. R., de Havenon, A., Rosand, J. M., Hanley, D. F., Ziai, W., Mayer, S. A., Woo, D., et al. (2024) · Annals of Neurology · doi:10.1002/ana.27123 · Cited by 13
Self-citationHu, X., Wang, M., Wang, Z., Xie, Y., Zhang, M., Zhang, S., Yang, T., Fang, C., Zhao, L., Tian, Y., et al. (2025) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864241311130 · Cited by 10
Ren, X., Huang, Q., Qu, Q., Cai, X., Fu, H., Mo, X., Wang, Y., Zheng, Y., Jiang, E., Ye, Y., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004349 · Cited by 11
Varela, S., Carrera, D., Elazim, A. A., Robinson, M. B., Torbey, M., & Carlson, A. P. (2022) · Operative Neurosurgery · doi:10.1227/ons.0000000000000408 · Cited by 10
[In-hospital mortality due to stroke].
Lucci, F. R., Lereis, V. P., Ameriso, S. F., Povedano, G. P., Díaz, M. F., Hlavnicka, A. A., Wainsztein, N. A., & Ameriso, S. F. (2013) · PubMed · Cited by 10
Management of Spontaneous Nontraumatic Intracranial Hemorrhage
Parker, D. L., Rhoney, D. H., & Liu‐DeRyke, X. (2010) · Journal of Pharmacy Practice · doi:10.1177/0897190010372320 · Cited by 11
“Thrombotic complications are a concern, and the best available data regarding the incidence is roughly 5%, which is derived from 2 randomized trials of rFVIIa for the treatment of spontaneous ICH.(33,34)”
BackgroundLow-dose recombinant factor VIIa for massive bleeding
Mordasini, A., Luginbühl, M., Regli, B., Kohler, H., Inderbitzin, D., Lämmle, B., & Alberio, L. (2011) · Swiss Medical Weekly · doi:10.4414/smw.2011.13213 · Cited by 10
Dong, J., Yang, X., Xiang, J. Y., Dong, Q., Tang, Y., & Chu, H. (2018) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2018.11.032 · Cited by 10
Comparison of Spontaneous Intracerebral Hemorrhage Treatment in Germany Between 1999 and 2009
Roth, C., Kästner, S., Salehi, M., Kleffmann, J., Böker, D.-K., & Deinsberger, W. (2012) · Stroke · doi:10.1161/strokeaha.112.670703 · Cited by 10
Evidence against rapid reversal of antiplatelet medications in acute intracerebral hemorrhage
Broderick, J. P. (2009) · Neurology · doi:10.1212/01.wnl.0000343513.94534.d2 · Cited by 10
Self-citationAdvances in Critical Care and Emergency Medicine 2007
Mayer, S. A., & Schwab, S. (2008) · Stroke · doi:10.1161/strokeaha.107.511832 · Cited by 10
Self-citationFactors affecting outcome after primary intracerebral hemorrhage
Tetri, S. (2009) · Cited by 11
Yoshimura, S. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22027 · Cited by 9
Reyes‐Esteves, S., Majumder, A., Marzolini, N., Zamora, M. E., Jeong, S., Wang, Y., Patel, M. N., Espy, C. L., Papp, T. E., Akyianu, A., et al. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03541-0 · Cited by 12
“Increased hematoma burden is strongly correlated with worse outcomes after ICH [7, 50, 53, 54] and thus, many have sought to develop ICH therapies that target hematoma, such as platelet transfusions or promoting coagulation [55, 56], but these strategies have failed.”
Acute management of spontaneous intracerebral hemorrhage (ICH) in the emergency department
Puissant, M. M., & Ganti, L. (2026) · International Journal of Emergency Medicine · doi:10.1186/s12245-026-01126-z · Cited by 9
“Elevated ICP related to mass effect from initial [37].”
Mao, S., Huang, H., & Chen, X. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/3017312 · Cited by 9
“Intracerebral hemorrhage (ICH) refers to primary cerebral intracephalic bleeding, which accounts for 10%-20% of all strokes [1], and is one of them with few effective therapeutic approaches confirmed by evidence-based medicine [2, 3].”
BackgroundRetractedChen, Y., Chang, J., Liu, J., Ye, Z., Tian, F., Ma, W., Wei, J., Feng, M., & Wang, R. (2022) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2022.106692 · Cited by 9
Xia, X., Zhang, X., Cui, J., Jiang, Q., Guan, S., Liang, K., Wang, H., Wang, C., Huang, C., Dong, H., et al. (2023) · NeuroImage Clinical · doi:10.1016/j.nicl.2023.103378 · Cited by 10
“As a potentially preventable factor, HE has been used as a plausible therapeutic target for anti-expansion treatment in many clinical trials (Mayer et al., 2008; Steiner and Bo ¨ sel, 2010; Qureshi et al., 2016; Sprigg et al., 2018).”
BackgroundYang, W., Liu, J.-Y., Shen, Y., Xie, X., Zhang, S., Liu, F.-Y., Yu, J.-L., Ma, Y.-B., Xiao, Z., Duan, H.-W., et al. (2024) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2024.107731 · Cited by 9
Drug delivery strategy of hemostatic drugs for intracerebral hemorrhage
An, J., Liu, Z., Wang, Y., Ke, M., Wang, Y., Sun, H. X., Li, M., & Tang, Z. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.01.007 · Cited by 9
Smith, J. E. (2012) · Emergency Medicine Journal · doi:10.1136/emermed-2012-201334 · Cited by 9
Prakash, B., Hu, J., Morgan, T. C., Hanley, D. F., & Nowinski, W. L. (2012) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0b013e318245c1fa · Cited by 9
Caplan, L. R. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4721-6.50015-8 · Cited by 10
Phan, T. G., Chen, J., Beare, R. J., Ma, H., Clissold, B. G., Ly, J. V., & Srikanth, V. K. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00064 · Cited by 9
“The recombinant factor VII trial had an average ICH volume 24 ± 26 and 23 ± 26 ml in the two treatment arms compared to 22 ± 24 ml in the placebo arm (13).”
BackgroundMethodResultInfluentialOvesen, C., Jakobsen, J. C., Gluud, C. N., Steiner, T., Law, Z. K., Flaherty, K., Dineen, R. A., Bath, P. M., Sprigg, N., & Christensen, H. (2018) · BMC Research Notes · doi:10.1186/s13104-018-3481-8 · Cited by 9
“However, previous trials randomising intracerebral haemorrhage patients to recombinant factor VII did observe an increased risk of thromboembolic events related to the treatment [12].”
BackgroundSelf-citationAssociation between Non-Alcoholic Fatty Liver Disease and Intracerebral Hemorrhage
Tu, S., Zhao, R., Fang, H., Wang, L., Shao, A., & Sheng, J. (2019) · Cell Transplantation · doi:10.1177/0963689719840025 · Cited by 9
Sarma, A. K., Ghoshal, S., Craven, S. J., & Sarwal, A. (2019) · Journal of Neuroanaesthesiology and Critical Care · doi:10.1055/s-0039-1689740 · Cited by 8
Cai, B., Lin, P., Wang, Z.-B., Zhang, M., & Peng, B. (2020) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2020.104793 · Cited by 11
Hemostasis, Coagulation Abnormalities, and Liver Disease
Mackavey, C. L., & Hanks, R. (2013) · Critical Care Nursing Clinics of North America · doi:10.1016/j.ccell.2013.09.001 · Cited by 9
Thrombin Causes Neuronal Atrophy and Acute but not Chronic Cell Death
Caliaperumal, J., Brodie, S. M., Ma, Y., & Colbourne, F. (2014) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2014.105 · Cited by 9
“6 An interesting consequence of these effects is that treatments that promote thrombin production to limit hematoma expansion, such as rFVIIa, 30 might counterproductively increase peri-hematoma cell death and atrophy thereby negating the beneficial effects of reducing hematoma size.”
Commonly used drugs in hematologic disorders
Anderes, E., & Nand, S. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-7020-4087-0.00076-0 · Cited by 9
Maragkos, G. Α., Nelton, E. B., Richter, S., & Stippler, M. (2020) · World Neurosurgery · doi:10.1016/j.wneu.2020.06.069 · Cited by 9
Clot Formation, Vascular Repair and Hematoma Resolution After ICH, a Coordinating Role for Thrombin?
Keep, R. F., Xi, G., Hua, Y., & Xiang, J. (2011) · Acta neurochirurgica. Supplementum · doi:10.1007/978-3-7091-0693-8_12 · Cited by 9
“Increasing thrombin production to prevent hematoma expansion was the basis of the Factor VIIa trial [ 2 ].”
Method
Metadata
- Authors
- Mayer, S. A., Brun, N. C., Begtrup, K., Broderick, J., Davis, S., Diringer, M. N., Skolnick, B. E., & Steiner, T.
- Affiliations
- Columbia University Irving Medical Center (US)
- Novo Nordisk (Denmark) (DK)
- University of Cincinnati Medical Center (US)
- The Royal Melbourne Hospital (AU)
- Washington University in St. Louis (US)
- Heidelberg University (DE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-05-15
- Volume
- 358
- Issue
- 20
- Pages
- 2127-2137
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2142640478
- Cited by
- 1,255
- References
- 29
- Citations by year
- 2026: 26 · 2025: 34 · 2024: 44 · 2023: 36 · 2022: 38 · 2021: 75 · 2020: 71 · 2019: 57 · 2018: 59 · 2017: 75 · 2016: 60 · 2015: 68 · 2014: 77 · 2013: 90 · 2012: 105
- FWCI
- 70.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
- Health Sciences › Medicine › Clinical Neurology › Intracranial Aneurysms: Treatment and Complications
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- recombinant factor VIIa, intracerebral hemorrhage, hematoma expansion, hemorrhagic stroke, thromboembolic adverse events, functional outcome, modified Rankin Scale, hemostatic therapy, dose comparison, arterial events, bleeding complications, arterial thrombosis, venous thromboembolism
- MeSH terms
- Adult, Aged, Aged, 80 and over, Cerebral Hemorrhage, Double-Blind Method, Female, Hematoma, Humans, Male, Middle Aged, Recombinant Proteins, Tomography, X-Ray Computed, Glasgow Coma Scale, Factor VIIa, Treatment Failure, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.